• {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pselfProduct%}
      • {%cSlanguages%}

    • AQUIPTA ER EN ORAL CGRP-ANTAGONIST2


      Aquipta tilhører gruppen gepanter og er små molekyler. Det er 250 ganger mindre enn monoklonale antistoffer (mAbs).3 Aquipta (atogepant) binder seg selektivt til flere reseptorer i kalsitonin/CGRP-reseptorfamilien.Dermed blokkeres effektene av CGRP ved trigeminusnerven samt i ekstrakranielle blodårer, som fører til migrenesymptomer.


      AQUIPTA blokkerar CGRP-BINDING

      Referanser:

      1. www.legemiddelsok.no (lesedato: 02.2024). 

      2. AQUIPTA (atogepant) SPC 11.08.2023, avsnitt 4.1, 5.1.

      3. Altamura C, Brunelli N, Marcosano M et al. Gepants — a long way to cure: a narrative review. Neurological Sciences (2022) 43:5697–5708.

      4. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350.

      Referanser MoA film:

      1. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nature Reviews Neurology. 2018 Apr 24;14(6):338–50.

      ‌2. Durham PL. CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? New England Journal of Medicine. 2004 Mar 11;350(11):1073–5.

      ‌3. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews [Internet]. 2017 Apr;97(2):553–622.

      4. Holland PR, Goadsby PJ. Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. Neurotherapeutics [Internet]. 2018 Mar 19;15(2):304–12. 

       

      NO-AQP-230004_v4, mai 2024